NORTH OLMSTED, Ohio, Oct. 27, 2020 /PRNewswire/ -- Two industry leaders are setting the new standard for homebuilding by connecting homeowners to their water in a way they've never experienced before. Moen, the leader in smart water technology, and Lennar, one of the nation's leading homebuilders, are joining forces to put the Flo by Moen™ Smart Water Shutoff in Lennar homes nationwide. This best-in-class, all-in-one water security system will give Lennar homeowners complete control over their home's water from anywhere and at any time.
Home industry giants Moen and Lennar join forces to put the Flo by Moen Smart Water Shutoff in Lennar homes nationwide
"Connected homes are quickly becoming the expectation for many new homebuyers," says Mark-Hans Richer, chief marketing and innovation officer, Moen. "We're raising the bar by using smart home technology to give homeowners across the country complete control over their home's water, 24/7."
From monitoring water usage in real time, to setting water conservation goals, the Flo by Moen Smart Water Shutoff gives homeowners all the data they need to understand, control and conserve their home's water. And with the device's innovative leak detection technology, homes will now have enhanced protection against unforeseen water events. A recent study with Lexis Nexis* showed that one year following installation of the Flo by Moen Smart Water Shutoff, homes saw a 96 percent decrease in paid water leak insurance claims compared to two years prior to installation. Now, Lennar homeowners will benefit from this proven water security solution.
"At Lennar, we're constantly focused on improving the future of home ownership, building homes to last that include the lifestyle preferences our customers want – including sustainable and connected features," says Eric Feder, managing general partner, LENX. "By integrating the Flo by Moen Smart Water Shutoff as a standard offering on our smart homes, we're bringing incredible value to our customers, helping them to protect their homes from the threat of water damage and leaks, helping them conserve water through leak detection and helping make their homes more sustainable, and enabling them to live the connected lifestyle they desire. Depending on their carrier, they may even be able to receive significant savings on their insurance premiums, thanks to the device's superior leak detection capabilities."
The Flo by Moen Smart Water Shutoff will be offered on newly built Lennar homes, providing Lennar customers with whole-home water security. Flo by Moen connects to the home's main water line and calculates pressure, flow rate and ambient temperature within the home's water supply system – delivering data to the homeowner via the Flo by Moen smartphone app. This enables the device to monitor and help detect water leaks and other vulnerabilities in the water supply system. If a leak is detected, it will either alert a homeowner to turn off the water supply through their app, or turn off the water supply automatically, if the homeowner chooses that setting. The app also gives homeowners a better understanding of their water usage, including usage by fixture – in real time – and allows them to set conservation goals.
"Forty percent of homeowners will suffer from some type of water damage," says Gabriel Halimi, CEO of Flo Technologies. "Forty percent. By including Flo by Moen in their builds, Lennar is leveraging our proprietary machine learning technology to help protect their customers' home water supply and allow them to enjoy all the many benefits of a smart water system, including an improved ability to monitor, control and conserve their home's water at their fingertips."
Flo by Moen also benefits home insurance customers. Hippo is a high-growth insurtech group that's transforming home insurance with a goal to provide customers with the tools and services they need to better protect their homes.
"This is an industry-leading initiative that will bring better value and real smart home functionality for homeowners," said Yuval Harry, Hippo's chief revenue officer. "Smart devices have the potential to drive down risk and ultimately insurance claims while giving homeowners the opportunity to secure meaningful savings on their insurance premiums with smart home discounts. We're very excited about the benefits this initiative will bring, in addition to our own work with Lennar, to arm homeowners with the best tools, services and insurance policies to keep their homes protected."
Moen's network of smart water products also includes the U by Moen™ Smart Shower and Smart Kitchen Faucet – both of which allow consumers to control and personalize their experiences with water – as well as the Flo by Moen™ Smart Water Detectors, which monitor for leaks outside the plumbing system. Together, this whole-home, smart water ecosystem offers products that not only look beautiful, but respond more intuitively, are more personalized and give consumers more control over using water to improve their health, comfort, security and peace of mind.
To learn more about Moen, visit moen.com or call 1-800-BUY-MOEN (1-800-289-6636).
ABOUT MOENMoen is the #1 consumer faucet brand in North America, offering a vast array of stylish and innovative kitchen and bath faucets, showerheads, accessories, bath safety products, kitchen sinks, garbage disposals, leak detection products and connected home offerings for residential applications that give consumers more power than ever before to understand and control the water that flows through their homes. These thoughtful designs deliver an exceptional user experience and elevate the way people interact with water every day. In addition, Moen® Commercial offers superior-performing products that can deliver lower lifetime costs for today's facilities.
Moen is part of Fortune Brands Home & Security, Inc. (NYSE: FBHS), which creates products and services that fulfill the dreams of home. Moen anchors the Global Plumbing Group (GPG), which also includes several brands under the House of Rohl® including Perrin & Rowe®, ROHL®, Riobel®, Shaws® and Victoria + Albert®. Fortune Brands' other brands include Fiberon® composite decking and railing products, Master Lock® and Sentry® Safe security products, MasterBrand Cabinets® and Therma-Tru® entry door systems. Fortune Brands is part of the S&P 500 Index. For more information, please visit www.FBHS.com.
ABOUT LENNARLennar Corporation, founded in 1954, is one of the nation's leading builders of quality homes for all generations. Lennar builds affordable, move-up and active adult homes primarily under the Lennar brand name. Lennar's Financial Services segment provides mortgage financing, title and closing services primarily for buyers of Lennar's homes and, through LMF Commercial, originates mortgage loans secured primarily by commercial real estate properties throughout the United States. Lennar's Multifamily segment is a nationwide developer of high-quality multifamily rental properties. LENX drives the Company's technology, innovation and strategic investments. For more information about Lennar, please visit www.lennar.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/home-industry-giants-to-expand-smart-water-technology-to-more-homes-301160837.html
COVID-19, Artificial Intelligence, New Implantable Kidneys, Clinical Trials, Precision Medicine
WASHINGTON, Oct. 21, 2020 /PRNewswire/ -- The American Association of Kidney Patients (AAKP), the largest independent kidney patient organization in the USA, and strategic partner George Washington University (GW) School of Medicine & Health Sciences (SMHS) shattered their virtual engagement record with their second annual Global Summit, "Global Kidney Innovations – Expanding Patient Choices & Outcomes," hosted July 16-17, 2020. The Global Kidney Innovations Summit has become the world's largest patient-led kidney innovation conference.
The Summit engaged participants in over 70 countries and included over 20 special medical and patient expert sessions on: COVID-19 impacts on the kidney and kidney patients; artificial intelligence and early disease diagnosis; greater diversity in clinical trials; precision medicine; genetic conditions such as APOL1; wearable and artificial implantable devices; and advancements in home dialysis care. Tens of thousands of patients, clinical trial experts, pharmaceutical researchers, medical professionals, and policy leaders worldwide participated in the virtual Summit.
The Summit is part of AAKP's Decade of the Kidney™, a strategic ten-year global innovation and collaborative initiative announced last year upon the signing of the historic bipartisan White House Executive Order on Advancing American Kidney Health.
The meeting was opened by Dr. Griffin Rodgers, Director of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and Chief of the Molecular and Clinical Hematology Branch at the U.S. National Institutes of Health (NIH). Dr. Rodgers is an international voice for patient inclusion in research and innovation, a research investigator, and is widely recognized for his contributions to the development of hydroxyurea, the first effective and FDA-approved therapy for sickle cell anemia. Dr. Rodgers is the recipient of the 2018 President's Medal from the American Society of Nephrology (ASN) and a member of the American Board of Internal Medicine (ABIM) Board of Directors. Watch Dr. Rodgers' remarks during the Global Summit.
AAKP President Richard Knight, a 14-year kidney transplant recipient, stated, "Kidney disease is a devastating disease that is rapidly expanding and negatively impacting patients, families, and economies throughout the world. Future innovations in kidney medicine depend upon greater patient engagement through fully inclusive clinical trials and research, and the GW School of Medicine & Health Sciences is a global leader in this field. I thank Dean Dr. Barbara Bass and Dr. Dominic Raj for their respect for patients and their efforts to unite patients and clinicians in the fight against all kidney diseases." Knight serves on the NIH/NIDDK Advisory Council, is Co-Chair of the Strategic Plan Stakeholder Engagement Subgroup, and Co-Chair of the Community Engagement Committee for the Kidney Precision Medicine Project (KPMP). Knight is a nationally known kidney advocacy leader.
Dr. Dominic Raj, Co-Chair of the Global Summit and Professor of Medicine and Chief of the Division of Kidney Diseases and Hypertension for GW SMHS, stated, "Excellence is never an accident, but a mark of persistence and teamwork. Two great institutions with a synergistic goal partnered to take this meeting to the Summit, powered by the motivating spirit of kidney patients. This year's Summit showcased not only the dire need for innovative discoveries and patient engagement, but also the significant progress made in the global arena in the field of nephrology."
Paul T. Conway, Co-Chair of the Global Summit and AAKP Chair of Policy and Global Affairs, said, "AAKP and our friend Dr. Dominic Raj designed the Global Summit on Kidney Innovations to be a distinct international event aimed at accelerating cooperation among patients, researchers, clinicians, and policy professionals. Kidney patient consumers worldwide demand far greater care choice and are well aware of the unique value their patient preference information has among innovation leaders driving the next generation of diagnostics, devices, and biologics. AAKP is prepared to work with patients worldwide to defend and advance the ideas of courageous innovation leaders through regulatory, legislative, and payment processes to solve the problem of kidney disease." Conway is a 23-year kidney transplant recipient and a former home peritoneal dialysis patient. He serves on the NIH/NIDDK External Expert Panel for the KPMP, is a member of the ABIM Nephrology Specialty Board, and a Patient Voice Editor for The Clinical Journal of the American Society of Nephrology (CJASN).
Knight and Conway are recipients of the 2017 ASN President's Medal. During the Summit, AAKP announced a strategic partnership with the Renal Patient Support Group (RPSG), a United Kingdom (UK) international evidence-based patient group. The organizations are committed to accelerating links among kidney patients worldwide to elevate patient insights among an international network of researchers, clinical trial experts, innovators, companies, and government leaders. This ground-breaking announcement is the first of its kind in the kidney patient community and signals widening support for an International Kidney Consortium.
All 2020 Global Summit presentations are available OnDemand and will continue to reach tens of thousands of additional viewers across the world to increase the AAKP and GW SMHS reach of this year's Global Summit. The Inaugural AAKP/GW event in 2019 engaged just over 50 countries and a combined in-person and worldwide audience exceeding 20,000.
AAKP and GW SMHS thanks its 2020 Global Summit sponsors: Amgen, Inc.; CareDx, Inc.; Natera; Eurofins Transplant Genomics; Outset Medical; and Retrophin. Information on the 2021 Global Summit will be listed at https://aakp.org/programs-and-events/2nd-annual-global-summit-global-kidney-innovations-expanding-patient-choices-outcomes/ as it becomes available.
MEDIA CONTACT: Jennifer DuplessieMarketing & Communications Managerjduplessie@aakp.org(813) 400-2394
Logo - https://mma.prnewswire.com/media/596158/AAKP_Logo.jpg
SOURCE American Association of Kidney Patients
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that it has submitted the Marketing Authorisation Application (MAA) for its lead product LUMEVOQ® to the European Medicines Agency (EMA), seeking approval for the treatment of patients with vision loss due to Leber Hereditary Optic Neuropathy (LHON) caused by mutation in the ND4 mitochondrial gene.
"This first regulatory submission for GenSight is a major milestone in our progression from a pure research organization to one with commercial capabilities. It validates a technology platform that has the potential to address the high unmet medical needs of patients suffering from a range of rare diseases. I would like to thank all GenSight employees and partners whose motivation, focus and effort made this submission possible,” said Bernard Gilly, Co-founder and Chief Executive Officer of GenSight Biologics.
LHON is a rare, mitochondrial genetic disease, mainly affecting young males. The ND4 mutation results in the worst visual outcomes, with most patients becoming legally blind. There continues to be a high unmet medical need for the 800-1200 new LHON patients in Europe and the U.S. each year, particularly those who are struck blind in their prime working years.
Lenadogene nolparvovec (tradename: LUMEVOQ®) is a recombinant adeno-associated viral vector, serotype 2 (rAAV2/2), containing a cDNA encoding the human wild-type mitochondrial NADH dehydrogenase 4 protein (ND4), which has been specifically developed for the treatment of LHON associated with mutation in the ND4 gene. It received orphan drug designation status for the treatment of LHON from the EMA in 2011 and from the U.S. Food and Drug Administration (FDA) in 2013.
GenSight submitted the MAA based on the benefit-risk balance established by results from a Phase-I/IIa study (CLIN-01), two pivotal Phase-III efficacy studies (CLIN-03A: RESCUE, and CLIN-03B: REVERSE) and the long-term follow up study of RESCUE and REVERSE (CLIN 06 - readout at Year 3 post injection). To demonstrate the efficacy of LUMEVOQ® in the context of a contralateral effect, the Company used a statistics-based indirect comparison methodology to assess the visual outcomes in LUMEVOQ®-treated patients (from LUMEVOQ® efficacy studies) against those in untreated patients from Natural History studies and GenSight’s REALITY Natural History Registry.
GenSight expects to submit the Biologics License Application (BLA) for LUMEVOQ® to the FDA in H2 2021. First-in-human data from GenSight’s second clinical stage program, GS030, are expected to be available in H2 2021.
About GenSight Biologics GenSight Biologics S.A. is a clinical-stage biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics’ lead product candidate, LUMEVOQ® (GS010; lenadogene nolparvovec), is in Phase III trials in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to the eye by intravitreal injection to offer patients a sustainable functional visual recovery.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200914005857/en/